Corvus Pharmaceuticals, Inc. — Director's Dealing 2021

Oct 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2021-09-30

Reporting Person: EcoR1 Capital, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-30	Common Stock	S	3000000	$5.0437	Disposed	2081077	Indirect
2021-10-01	Common Stock	S	2000000	$4.9644	Disposed	81077	Indirect

Footnotes

F1: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction.

F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

F3: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction.